Ambient Voice Technology (AVT), once considered a speculative innovation, is rapidly evolving into a strategic necessity for healthcare organizations. Fuelled by an urgent need to combat clinician burnout, address rising administrative workloads, and enhance operational efficiency, AVT is poised to fundamentally reshape the clinical workflow. The market is transitioning from an experimental phase to a mature, regulated ecosystem where this technology is no longer a luxury but

Nelson Advisors Partner Lloyd Price invited to speak on the Investor Forum at the Global Health Exhibition 2025 in Riyadh, Saudi Arabia #GHE25 . The Investor Forum at the Global Health Exhibition 2025 is a premier platform for investors, innovators, and healthcare leaders to explore transformative investment opportunities in Saudi Arabia’s rapidly evolving healthcare landscape.

Nelson Advisors partner Lloyd Price interviewed by Digital Health for their 'NHS App to unleash its full potential' story. Lloyd Price, partner at Nelson Advisors and health tech founder, said that the NHS App needs a “killer feature” to increase its usage and “unlock further organic and viral growth”. He added that the main functions of the NHS App to book GP appointments and order repeat prescriptions can be done through other apps such as Patient Access from EMIS, MyGP fr

The European HealthTech market in 2026 is at a pivotal juncture, moving from a period of early-stage experimentation to a more grounded, results-oriented reality. Success for all stakeholders—from innovative founders to strategic buyers—is predicated on navigating a complex and converging landscape defined by regulatory maturation, a selective funding environment, and an accelerated trend of market consolidation. The core thesis of this report is that a strategic shift is req

The global MedTech sector is entering a new era of mergers and acquisitions (M&A) characterised by a pronounced shift from broad portfolio expansion to highly selective, technology-driven acquisitions. While the broader healthcare M&A landscape experienced a decline in deal volume and value in 2024, the MedTech sub-sector demonstrated remarkable resilience. This report highlights that a period of market resurgence is underway, driven by a strategic focus on a smaller number o

Nelson Advisors Partner Lloyd Price has been invited to Judge the 'HealthInvestor Power List 2025 Awards' recognising the most effective, inspiring and influential leaders in Health and Social Care.

The integration of artificial intelligence (AI) into healthcare is not a question of if, but how. This report asserts that for AI to be implemented ethically and effectively, the nursing profession must be at the forefront of its development. Nurses are not merely the end-users of these technologies; they are the indispensable link between raw patient data and human-centered care. By shifting from a traditional technology-first approach to a collaborative, human-in-the-lo

The year 2026 is poised to be a pivotal year for the integration of artificial intelligence into healthcare, marked by the maturation of a new class of specialised systems known as Personal Health Large Language Models (PH-LLMs). These models represent a fundamental shift beyond general-purpose AI, moving from broad-based utility to domain-specific reliability. They are positioned to revolutionise the HealthTech landscape by acting as intelligent, reasoning engines that enhan

Nelson Advisors Partner Lloyd Price will lead the 'HealthTech M&A and IPOs Panel' at the Global Health Exhibition 2025 in Riyadh, Saudi Arabia. #GHE25 The Global Health Exhibition in Riyadh is a major event focused on healthcare innovation, investment, and transformation. It brings together global leaders from both the public and private sectors to discuss the future of healthcare.

Venture debt has emerged as a critical and purpose-built financial instrument within the dynamic and capital-intensive health technology (healthtech) sector. This report provides an analysis of its strategic role, delineating its distinct strengths, inherent weaknesses, current opportunities and future trajectory. Venture debt is defined as a specialised loan for high-growth, venture-backed startups, uniquely underwritten based on a company's ability to raise future equity ra

The health technology sector is experiencing a period of intense focus on artificial intelligence, driven by an "AI-first" narrative that has captivated investors and dominated industry discourse. This report posits that this concentrated market behaviour, characterised by an investment "gold rush," presents a profound opportunity for a contrarian business strategy. The prevailing AI narrative, much like other market frenzies, has led to a collective overvaluation of a single

The global HealthTech landscape is undergoing a profound structural transformation. A confluence of economic headwinds in mature markets, particularly in North America and a recalibration of investor sentiment away from speculative growth has positioned cross-border mergers and acquisitions (M&A) as the primary engine of strategic growth and liquidity. This report presents a detailed analysis of this new paradigm, arguing that strategic buyers, from big Pharma and health

The healthcare industry is on the cusp of a profound transformation, shifting from a traditional model of patient engagement to an increasingly automated, self-directed paradigm. Patient engagement, a cornerstone of value-based care, has historically relied on a collaborative, human-centric partnership between patients and their care teams. However, this model faces inherent limitations in scalability due to administrative burdens, staffing shortages, and the increasing compl

This report provides a comprehensive analysis of Nelson Advisors LLP, a highly specialised London-based M&A and corporate advisory firm, and its strategic role in assisting healthcare technology (HealthTech) and MedTech companies with UK market entry. A central finding is the firm's use of a "Build, Buy, Partner, Sell" framework, which transcends traditional transactional advisory. This holistic model guides clients, particularly Western European and North American compan

The MedTech M&A landscape in Europe in 2025 has shifted fundamentally, moving away from a strategy of broad asset aggregation to one of selective, high-value and strategically aligned investments. This new era of strategic selectivity is defined by a central thesis: acquirers are placing high-conviction bets on mature, innovative companies that offer a clear path to long-term growth and operational efficiency. The market, despite lingering macroeconomic uncertainties, is demo